TREATMENT FOR cancer is becoming increasingly complicated. New classes of drugs and innovative approaches to therapy involving immunologic manipulation have resulted in fascinating side effects in the skin. In many instances, these side effects are referable to a specific agent and result in increased understanding of the pathophysiologic changes of the skin. In this issue, Valks et al1 report the clinicopathologic correlation between the histologic finding of eccrine squamous syringometaplasia (ESS) and the cutaneous eruptions sampled from 10 patients receiving high-dose antineo-plastic chemotherapy with bone marrow or peripheral blood stem cell support in the treatment of various malignant neoplasms. These observations highlight the connection between the concentration of antineoplastic medications in eccrine sweat and subsequent clinical and histologic changes in the skin.
The secretory portion of the eccrine apparatus produces an isotonic to slightly hypertonic fluid, which becomes increasingly concentrated as water is removed with the passage of the
Horn TD. Antineoplastic Chemotherapy, Sweat, and the Skin. Arch Dermatol. 1997;133(7):905-906. doi:10.1001/archderm.1997.03890430123017